Pancreatic Cancer Research

ResearcherUniversity of ArizonaActive in the last 2 years

Muhammad Shaalan Beg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3754-6627; OpenAlex author ID A5014809735, A5110519572. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 1, last author 4)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2013: 1 trial · 2014: 1 paper · 2015: none · 2016: 1 paper, 1 trial · 2017: 2 papers · 2018: 3 papers · 2019: 2 papers, 1 trial · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 21

  1. Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-3582↗
  2. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. Co-author DOI 10.1016/j.gassur.2023.12.022↗
  3. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.013↗
  4. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  5. Survival of cancer survivors with a new pancreatic cancer diagnosis. Co-author DOI 10.1002/cam4.4903↗
  6. Ablative Radiation Therapy in Oligometastatic Pancreatic Cancer to Delay Polyprogression, Limit Chemotherapy, and Improve Outcomes. Co-author DOI 10.1016/j.ijrobp.2022.07.019↗
  7. Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis. Co-author DOI 10.2196/31388↗
  8. Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2020.7328↗
  9. Early Palliative Care Is Associated With Reduced Emergency Department Utilization in Pancreatic Cancer. Last author DOI 10.1097/coc.0000000000000802↗
  10. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-20-0860↗
  11. Targeting TAM to Tame Pancreatic Cancer. Last author DOI 10.1007/s11523-020-00751-9↗
  12. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectabl… Co-author DOI 10.1097/sla.0000000000004155↗
  13. Fasting and Glucose-Stimulated Changes in Plasma Glucagon in Pancreatic Cancer: Potential Biomarkers for Detection? Last author DOI 10.1097/mpa.0000000000001208↗
  14. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2019.7322↗
  15. Pancreatic Cancer Metabolism: Molecular Mechanisms and Clinical Applications. First author DOI 10.1007/s11912-018-0699-5↗
  16. Impact of Concurrent Medication Use on Pancreatic Cancer Survival-SEER-Medicare Analysis. Co-author DOI 10.1097/coc.0000000000000359↗
  17. Palliative care and end-of-life health care utilization in elderly patients with pancreatic cancer. Last author DOI 10.21037/jgo.2018.03.08↗
  18. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Co-author DOI 10.1002/jso.24624↗
  19. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. Co-author DOI 10.1074/jbc.m117.813923↗
  20. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Co-author DOI 10.1007/s00280-016-3108-5↗
  21. Impact of diabetes mellitus on the outcome of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0098511↗

Trials 3

  1. Biological Effect of Warfarin on Pancreatic Cancer Principal investigator NCT03536208↗
  2. ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer Principal investigator NCT02514031↗
  3. A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas Principal investigator NCT01838317↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrea Wang‐Gillam · 5 shared papers, 2020–2024 · strength 0.73
  2. Davendra P. S. Sohal · 4 shared papers, 2020–2024 · strength 0.58
  3. Andrew M. Lowy · 4 shared papers, 2020–2024 · strength 0.58
  4. Philip A. Philip · 4 shared papers, 2020–2024 · strength 0.58
  5. Elena Gabriela Chiorean · 4 shared papers, 2020–2024 · strength 0.58
  6. Todd Anthony Aguilera · 4 shared papers, 2019–2025 · strength 0.54
  7. Herbert J. Zeh · 4 shared papers, 2019–2025 · strength 0.54
  8. Nina Niu Sanford · 4 shared papers, 2019–2025 · strength 0.53
  9. Syed Mohammad Ali Kazmi · 3 shared papers, 2021–2025 · strength 0.43
  10. John C. Mansour · 3 shared papers, 2019–2025 · strength 0.36
  11. Arjun Gupta · 3 shared papers, 2018–2022 · strength 0.34
  12. Syed Arif Ahmad · 3 shared papers, 2014–2024 · strength 0.32
  13. Patricio Marcelo Polanco · 2 shared papers, 2022–2025 · strength 0.31
  14. Ahmed M. Elamir · 2 shared papers, 2022–2025 · strength 0.31
  15. Matthew R. Porembka · 2 shared papers, 2022–2025 · strength 0.31
  16. Syed Ameen Ahmad · 2 shared papers, 2021–2024 · strength 0.31
  17. Anna Tavakkoli · 2 shared papers, 2021–2023 · strength 0.29
  18. Sandi L. Pruitt · 2 shared papers, 2021–2023 · strength 0.29
  19. Rolf A. Brekken · 2 shared papers, 2020–2021 · strength 0.26
  20. Namita Sharma Gandhi · 2 shared papers, 2020–2021 · strength 0.22
  21. Howard S. Höchster · 2 shared papers, 2020–2021 · strength 0.22
  22. Philip Martin Arlen · 2 shared papers, 2016–2023 · strength 0.21
  23. Michael Andrew Morse · 2 shared papers, 2016–2023 · strength 0.21
  24. Nizar Bhulani · 2 shared papers, 2018–2021 · strength 0.20
  25. Victor Tsu-Shih Chang · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.